GEN Exclusives

More »

Market and Technology Analysis

More »
Oct 22, 2013

Biomarker Trajectories: Molecular Entities and Their Progression as Biomarkers

This report based on more than 92,000 publications illustrates biomarker trends over time.

Biomarker Trajectories: Molecular Entities and Their Progression as Biomarkers

Biomarkers over time. [Dmitry Sunagatov -]

  • The focus of this GEN Market & Tech Analysis report is to present some of our most recent analysis of publications trends across a number of biomarker classes with respect to time over the past five years as a way to map the trajectory of these molecular species.

    Specifically, we present here selected examples from the following classes:

    • Traditional biomarkers
    • microRNAs
    • Long noncoding RNAs
    • Epigenetics modifications

    This temporal analysis seeks to map the evolution of a particular marker—one at a time—and therefore provides a granular approach to understanding specific trends as they relate to specific molecular entities and drivers for their utilization/adoption in research as well as in clinical practice.

    Highlights of this GEN Report:

    • A comparative analysis of the complete set of biomarker-focused publications from the scientific literature illustrates the publication trends over time and enables a picture to be sketched of the expansion or contraction of a particular class of biomarkers.
    • Our analysis has been based on more than 92,000 publications which we’ve sorted and segmented into various classes based on the context in which they appear in the publication record.
    • We have compared various molecular species in this report excerpted from our comprehensive database of all of the common markers that have been described.
    • We’ve also compared in our analysis the molecular lesions that are the subject of companion diagnostics development and association with specific therapeutics in defined disease classes.
    • Finally, our database allows the interrogation of a particular molecular entity in order to ask whether any association[s] have been documented with specific disease classes, in this manner identifying “virgin territory” for potential IP protection.

    CLICK HERE to download the PDF report.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »